Recruitment

Recruitment Status
Completed

Inclusion Criterias

Consultation by the GCT
Dutch speaking
75 years or older
...
Consultation by the GCT
Dutch speaking
75 years or older
Admitted to a non-geriatric ward

Exclusion Criterias

End-of-life
No drugs on admission
End-of-life
No drugs on admission

Summary

Conditions
Iatrogenic Disease
Type
Interventional
Design
  • Allocation: Non-Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Health Services Research

Participation Requirements

Age
Between 75 years and 125 years
Gender
Both males and females

Description

Polypharmacy and (potentially) inappropriate prescribing is highly prevalent in the older population, associated with increase health care expenditures, morbidity and avoidable adverse events . The aim of this pilot study was to evaluate whether a systematic medication evaluation by a geriatric cons...

Polypharmacy and (potentially) inappropriate prescribing is highly prevalent in the older population, associated with increase health care expenditures, morbidity and avoidable adverse events . The aim of this pilot study was to evaluate whether a systematic medication evaluation by a geriatric consultation team (GCT) using the RASP (Rationalisation of drugs on admission by an adjusted STOPP-list in older patients) list could reduce inappropriate prescribing for older admitted patients, admitted to non-geriatric departments. The GCT could offer the ideal format to deliver the intervention to a broad older hospitalised population.

Inclusion Criterias

Consultation by the GCT
Dutch speaking
75 years or older
...
Consultation by the GCT
Dutch speaking
75 years or older
Admitted to a non-geriatric ward

Exclusion Criterias

End-of-life
No drugs on admission
End-of-life
No drugs on admission

Locations

Leuven, Flemish Brabant, 3000
Leuven, Flemish Brabant, 3000

Tracking Information

NCT #
NCT02165618
Collaborators
Not Provided
Investigators
  • Principal Investigator: Lorenz R Van der Linden, PharmD Universitaire Ziekenhuizen Leuven Principal Investigator: Johan Flamaing, MD, PhD Universitaire Ziekenhuizen Leuven Principal Investigator: Jos Tournoy, MD, PhD Universitaire Ziekenhuizen Leuven
  • Lorenz R Van der Linden, PharmD Universitaire Ziekenhuizen Leuven Principal Investigator: Johan Flamaing, MD, PhD Universitaire Ziekenhuizen Leuven Principal Investigator: Jos Tournoy, MD, PhD Universitaire Ziekenhuizen Leuven